HCC patients in the high-risk group had a significantly higher prevalence of TP53 (frequency: 46% vs. 15%, P < 0.05, Supplementary Tables 3–4), whereas a higher prevalence of CTNNB1 was presented in the low-risk group (frequency: 32% vs. 21%, P < 0.05, Supplementary Tables 3–4). This evidence concerns the gene TP53 and hepatocellular carcinoma.